Mr. Rowland is replacing Dr. Elazar Sonnenschein, Founder & CEO, who will Head Global Operations, starting October 1st, 2013.
Omer, Israel, 01 October, 2013 -- Medigus, Ltd. (TASE:MDGS), a leading medical device company dedicated to the development of innovative endoscopy-based surgical procedures and technologies, announced that the general assembly of its shareholders has approved the appointment of Mr. Christopher (Chris) Rowland as chief executive officer of the company.
Mr. Rowland, who has served as a director of Medigus since March 2013, is replacing Dr. Elazar Sonnenschein, a Founder and the current chief executive officer of the company. His appointment becomes effective today, October 1, 2013.
Dr. Sonnenschein, a founder of Medigus and its CEO since the company’s establishment in 2000, will assume the role of global chief operating officer, and will assist in Mr. Rowland's transition. In his role as global COO, Dr. Sonnenschein will be responsible for operations, manufacturing and R&D.
Mr. Rowland, 51, has twenty-five years’ experience in the life sciences market, specifically in the medical device and non-invasive medicine sectors. During his career he has held senior executive positions in the USA and overseas in both public and private companies, ranging from large multi-national corporations to small innovative companies. During 2006 - 2009, he served as president, Americas at Given Imaging, and was also a member of the company's Executive Committee. During his tenure, Given Imaging revenues in the U.S. doubled and operating profit increased. Prior to his position at Given Imaging, Mr. Rowland served seventeen years in positions of increasing responsibility at the Boston Scientific Corporation, including country manager for Israel and global vice president of marketing for the Endoscopy division. Most recently, Mr. Rowland served as CEO of NeoTract, Inc. and president of IntraPace, Inc.
Medigus is at the forefront of the transition from invasive gastric surgery procedures to advanced minimally invasive treatment techniques, particularly with regard to GERD (gastroesophageal reflux disease), which is increasing in global prevalence. The company’s SRS™ system allows treatment of chronic reflux by means of a one-time endoscopic procedure, which restores the patient's health and quality of life. The single-use SRS™ system achieves this without compromising safety or efficacy, as proven during previous clinical trials. Medigus' minimally invasive technology platform not only enhances patient care, but may also affect hospital and health insurer efficiency with lower costs and reduced hospitalizations.